Thiocolchishin dosage and administration
Reading File
Searching the Web
thiocolchicoside dosage administration guidelines 2024
Finding Sources
The medical library doesn't contain a specific entry for thiocolchicoside, but the EMA product information and web sources are authoritative. Here is the complete dosage and administration guide:
Thiocolchicoside - Dosage and Administration
Thiocolchicoside is a semi-synthetic muscle relaxant derived from colchicine, used as an adjunct therapy for acute muscle spasticity related to spinal pathology in adults and adolescents aged 16 years and above.
Dosage by Route
Oral (tablets/capsules - 4 mg or 8 mg)
| Parameter | Details |
|---|---|
| Recommended dose | 8 mg every 12 hours (16 mg/day maximum) |
| Maximum duration | 7 consecutive days |
| Administration | Take during or after meals to reduce GI irritation |
Intramuscular (IM) Injection
| Parameter | Details |
|---|---|
| Recommended dose | 4 mg every 12 hours (8 mg/day maximum) |
| Maximum duration | 5 consecutive days |
| Setting | Should be administered under physician supervision |
Topical Gel
| Parameter | Details |
|---|---|
| Frequency | 2-3 times daily, applied to the affected area |
| Duration | As directed; generally used for localized muscle pain |
| Note | Topical form has minimal systemic absorption |
Key Administration Points
- Adjunct use only: Thiocolchicoside is not a standalone therapy; it should be combined with physiotherapy or other analgesics.
- Short-term only: Long-term use must be avoided due to genotoxicity risk from the metabolite 3-demethylcolchicine (M2), which the EMA's CHMP review identified as capable of causing chromosomal abnormalities (aneuploidy) even at or near recommended doses.
- Exceeding recommended doses must be strictly avoided.
- Missed dose: Take as soon as remembered, but skip if the next dose is near. Never double dose.
Special Populations
| Population | Guidance |
|---|---|
| Children < 16 years | Contraindicated - safety not established |
| Pregnant women | Contraindicated throughout entire pregnancy |
| Breastfeeding women | Contraindicated |
| Women of childbearing potential | Contraindicated unless using reliable contraception |
| Elderly | Use with caution; no specific dose adjustment is established, but monitor closely |
| Hepatic/renal impairment | Use with caution; consult product-specific labeling |
Contraindications
- Hypersensitivity to thiocolchicoside or any excipient
- Pregnancy (entire duration)
- Lactation
- Women of childbearing potential not using effective contraception
- Age < 16 years
Common Side Effects
- GI: nausea, diarrhea, abdominal pain, bloating
- CNS: drowsiness, dizziness
- Serious (report immediately): allergic reactions (rash, itching), jaundice/dark urine (hepatotoxicity), seizures
Pharmacokinetics (Brief)
- Bioavailability (oral): ~25%
- Half-life: 5-6 hours
- Metabolism: converted to M2 (3-demethylcolchicine), a genotoxic metabolite - the primary reason for strict duration limits
Source note: The dosage limits above reflect the EMA Article 31 referral decision, which tightened restrictions on thiocolchicoside after a formal safety review. Always verify against the current approved product information for your region, as national labeling may vary slightly.
73077.jpg
73076.jpg
Find any fracture or abnormalities
analyse_media
analyse_media
Radiological Review - Sanu Shisha, 18 yr/M | 17-07-2026
Films reviewed:
- Chest AP view
- Bilateral Shoulder Joints AP view
X-Ray 1 - Chest AP
| Structure | Finding |
|---|---|
| Ribs (bilateral) | Intact cortical margins; no acute fractures |
| Clavicles | Both intact, no fracture or cortical disruption |
| Shoulder joints | Glenohumeral joints well-aligned bilaterally |
| Thoracic/Cervical spine | Normal alignment; no scoliosis; no vertebral height loss |
| Lung fields | Mild increase in bronchovascular markings perihilarly, likely positional (AP projection + suboptimal inspiration); no consolidation, nodules, or masses |
| Pleura | Costophrenic angles clear; no effusion, no pneumothorax |
| Mediastinum | Normal width; trachea midline; no hilar adenopathy |
| Heart | CTR within normal limits (accounting for AP magnification) |
| Soft tissues | No subcutaneous emphysema |
X-Ray 2 - Bilateral Shoulder Joints AP
| Structure | Right | Left |
|---|---|---|
| Glenohumeral joint | Normal alignment, joint space preserved | Normal alignment, joint space preserved |
| Proximal humerus | No fracture (head, neck, tuberosities intact) | No fracture, cortex intact |
| Clavicle | Intact | Intact |
| AC joint | Normal spacing and alignment | Symmetric, normal |
| Scapula | Acromion, coracoid, body intact | Intact |
| Soft tissues | No calcification, no swelling | No abnormality |
Impression
No acute fractures or dislocations identified on either the chest AP or bilateral shoulder joint views.The mild perihilar bronchovascular prominence on the chest film is most likely a technical/positional artifact (AP projection, low inspiratory volume) and is not suggestive of active cardiopulmonary pathology.
Important: This is an AI-assisted screening review and is not a substitute for a formal report by a qualified radiologist. Correlation with the patient's clinical history, mechanism of injury, and physical examination findings is essential for definitive management.
Thiocolchishin dosage and administration
This was answered earlier in our conversation. Here is the complete summary:
Thiocolchicoside - Dosage & Administration
By Route
| Route | Dose | Frequency | Max Duration |
|---|---|---|---|
| Oral (4 mg / 8 mg tablets) | 8 mg | Every 12 hours (16 mg/day max) | 7 consecutive days |
| IM Injection | 4 mg | Every 12 hours (8 mg/day max) | 5 consecutive days |
| Topical gel | Apply to affected area | 2-3 times daily | As directed |
Key Points
- Indication: Adjunct therapy for acute muscle spasticity related to spinal pathology
- Age restriction: Not for use in children/adolescents under 16 years
- Take oral form during or after meals to reduce GI upset
- Do not exceed recommended doses or duration - the metabolite M2 (3-demethylcolchicine) is genotoxic
- Not for chronic/long-term use
Contraindications
- Pregnancy (entire duration)
- Breastfeeding
- Women of childbearing potential without effective contraception
- Age < 16 years
- Hypersensitivity to the drug
Common Side Effects
- Nausea, diarrhea, abdominal pain, drowsiness
- Serious (report immediately): rash/allergic reaction, jaundice, seizures
Patient complaining Tramadol is not effective can I give aceclofenac instead
Reading File
Searching the Web
aceclofenac vs tramadol musculoskeletal pain switching analgesic
Finding Sources
Finding Sources
Reading File
Finding Sources
Can You Give Aceclofenac Instead of Tramadol?
Short answer: Yes - and for musculoskeletal pain, aceclofenac is often the better choice.
Why Tramadol May Not Be Effective
Tramadol's analgesic effect has significant inter-individual variability due to CYP2D6 metabolism. According to Miller's Anesthesia (10e):
"The dose of tramadol needed to relieve pain in 80% of patients (ED80) was 260 mg - much larger than the usual dose of 50-100 mg."
Poor metabolizers (CYP2D6 polymorphism) get little to no analgesic benefit from tramadol, because the active metabolite M1 is not produced adequately. This is a pharmacogenomic reason the drug may feel ineffective to your patient.
Why Aceclofenac is a Good Switch
| Feature | Tramadol | Aceclofenac |
|---|---|---|
| Class | Weak opioid (central) | NSAID / COX-2 preferential (peripheral + central) |
| Mechanism | μ-opioid receptor + NE/5HT reuptake inhibition | COX-1/COX-2 inhibition → ↓ prostaglandins + ↓ IL-1β, TNF-α |
| Best for | Neuropathic pain, post-op moderate pain | Musculoskeletal pain, joint pain, inflammation |
| GI risk | Lower | Moderate (take with food / PPI cover) |
| Variability | High (CYP2D6 dependent) | Low - predictable response |
| Addiction risk | Yes (opioid - Schedule H1) | No |
Aceclofenac also inhibits IL-1β synthesis and TNF-α release beyond pure COX inhibition, giving it an additional disease-modifying anti-inflammatory effect that tramadol lacks entirely.
Aceclofenac Dosage
| Form | Dose | Frequency |
|---|---|---|
| Tablet (100 mg) | 100 mg | Twice daily (with food) |
| Maximum daily dose | 200 mg/day | - |
| SR tablet (200 mg) | 200 mg | Once daily |
Clinical Recommendation for This Patient (18 yr, musculoskeletal/trauma)
Option 1 - Switch: Stop tramadol, start aceclofenac 100 mg BD with food. This is appropriate if:
- Pain is primarily inflammatory/musculoskeletal
- No GI ulcer history, normal renal function
Option 2 - Combine (multimodal analgesia): Aceclofenac 100 mg BD + low-dose tramadol (or paracetamol) for breakthrough pain - evidence supports NSAID + opioid combinations for additive effect via complementary mechanisms.
Option 3 - Aceclofenac + Thiocolchicoside (already prescribed): This is a well-established combination for musculoskeletal spasm with pain - very appropriate for this patient's presentation.
Cautions Before Prescribing Aceclofenac
- GI: Give with food; add a PPI (omeprazole 20 mg OD) if any GI risk
- Renal: Avoid or use cautiously if eGFR < 30 mL/min
- Cardiovascular: Avoid in patients with heart failure, recent MI, or uncontrolled hypertension
- Age 18 years: Safe in adults; no dose adjustment needed
- Duration: Short-term use preferred (5-7 days for acute pain); avoid prolonged use
Bottom line: For this 18-year-old with musculoskeletal/shoulder pain unresponsive to tramadol, switching to aceclofenac 100 mg BD is clinically rational, evidence-supported, and likely to be more effective given the inflammatory nature of the pain. Combined with thiocolchicoside, this provides a strong analgesic + muscle relaxant regimen appropriate for the presentation.
This is a shared conversation. Sign in to Orris to start your own chat.